JPMorgan Chase & Co. Has $110.70 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

JPMorgan Chase & Co. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,358,945 shares of the medical equipment provider’s stock after purchasing an additional 238,222 shares during the period. JPMorgan Chase & Co. owned approximately 0.60% of Hologic worth $110,700,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Black Creek Investment Management Inc. increased its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its holdings in Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the period. Marshall Wace LLP bought a new position in shares of Hologic during the second quarter worth $39,427,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after buying an additional 450,190 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.2 %

Hologic stock opened at $72.09 on Thursday. Hologic, Inc. has a twelve month low of $70.36 and a twelve month high of $84.67. The stock has a market cap of $16.36 billion, a P/E ratio of 21.65, a P/E/G ratio of 2.32 and a beta of 0.96. The company’s 50-day moving average price is $77.06 and its two-hundred day moving average price is $78.48. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the company earned $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on HOLX shares. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Raymond James increased their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average price target of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.